Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals Limited has announced the quotation of 8,300,335 ordinary fully paid securities on the ASX, effective from September 9, 2025. This move is part of the company’s strategy to enhance its market presence and provide additional value to its stakeholders by expanding its capital base.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for various diseases. The company is primarily engaged in creating treatments that address unmet medical needs, leveraging its expertise in drug repurposing and development.
Average Trading Volume: 834,288
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$113M
See more data about PAR stock on TipRanks’ Stock Analysis page.